<?xml version="1.0" encoding="UTF-8"?>
<ref id="pone.0231138.ref026">
 <label>26</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Mpendo</surname>
   <given-names>J</given-names>
  </name>, 
  <name>
   <surname>Mutua</surname>
   <given-names>G</given-names>
  </name>, 
  <name>
   <surname>Nyombayire</surname>
   <given-names>J</given-names>
  </name>, 
  <name>
   <surname>Ingabire</surname>
   <given-names>R</given-names>
  </name>, 
  <name>
   <surname>Nanvubya</surname>
   <given-names>A</given-names>
  </name>, 
  <name>
   <surname>Anzala</surname>
   <given-names>O</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.</article-title>
  <name>
   <surname>Richie</surname>
   <given-names>TL</given-names>
  </name>, editor. 
  <source>PLoS One.</source>
  <year>2015</year>;
  <volume>10</volume>: 
  <fpage>e0134287</fpage>
  <pub-id pub-id-type="doi">10.1371/journal.pone.0134287</pub-id>
  <?supplied-pmid 26252526?>
  <pub-id pub-id-type="pmid">26252526</pub-id>
 </mixed-citation>
</ref>
